We have located links that may give you full text access.
CASE REPORTS
JOURNAL ARTICLE
Rituximab therapy for life-threatining immune hemolytic anemia in a liver tranplant recipient: a case report.
Transplantation Proceedings 2004 June
Rituximab an anti-CD20 chimeric monoclonal antibody directed against the CD20 antigen on B lymphocytes, has been demonstrated to be highly effective for B-cell depletion. Because of its biological properties, it has become as a treatment option for a variety of autoimmune diseases. We report successful treatment of a 25-year-old male cadaveric liver retransplant recipient who displayed severe immune hemolytic anemia with rituximab, despite no previous response to corticosteroids plus intravenous immune globulin therapy.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app